Updated:
SOLENO THERAPEUTICS INC
At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS)...
SOLENO THERAPEUTICS INC
At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
Corporate office
United States
Sector focus
Frequently asked questions
What drug candidate is Soleno currently developing?
Soleno's lead asset is DCCR (diazoxide choline), a once-daily oral tablet for Prader-Willi syndrome (PWS), a rare genetic disorder. DCCR is intended to treat hyperphagia (extreme hunger) and other symptoms of PWS (per company Phase 3 data, 2024). The company has completed pivotal trials and is preparing for FDA submission.
Does Soleno Therapeutics invest in other companies or funds?
No public disclosures indicate that Soleno makes external investments in other companies or funds. Its capital is allocated solely to internal R&D and clinical development of DCCR. The firm is a drug developer, not an investment vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: